- Home
- LNZA vs IMMX Comparison
LNZA vs IMMX Comparison
Compare LNZA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- IMMX
- Stock Information
- Founded
- LNZA 2005
- IMMX 2014
- Country
- LNZA United States
- IMMX United States
- Employees
- LNZA N/A
- IMMX N/A
- Industry
- LNZA Major Chemicals
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- LNZA Industrials
- IMMX Health Care
- Exchange
- LNZA Nasdaq
- IMMX Nasdaq
- Market Cap
- LNZA 65.7M
- IMMX 61.1M
- IPO Year
- LNZA N/A
- IMMX 2021
- Fundamental
- Price
- LNZA $0.28
- IMMX $2.55
- Analyst Decision
- LNZA Hold
- IMMX Strong Buy
- Analyst Count
- LNZA 2
- IMMX 1
- Target Price
- LNZA $2.00
- IMMX $7.00
- AVG Volume (30 Days)
- LNZA 2.3M
- IMMX 145.9K
- Earning Date
- LNZA 08-07-2025
- IMMX 08-11-2025
- Dividend Yield
- LNZA N/A
- IMMX N/A
- EPS Growth
- LNZA N/A
- IMMX N/A
- EPS
- LNZA N/A
- IMMX N/A
- Revenue
- LNZA $48,831,000.00
- IMMX N/A
- Revenue This Year
- LNZA $58.17
- IMMX N/A
- Revenue Next Year
- LNZA $10.92
- IMMX N/A
- P/E Ratio
- LNZA N/A
- IMMX N/A
- Revenue Growth
- LNZA N/A
- IMMX N/A
- 52 Week Low
- LNZA $0.14
- IMMX $1.26
- 52 Week High
- LNZA $2.74
- IMMX $3.00
- Technical
- Relative Strength Index (RSI)
- LNZA 50.36
- IMMX 61.17
- Support Level
- LNZA $0.25
- IMMX $2.16
- Resistance Level
- LNZA $0.33
- IMMX $2.31
- Average True Range (ATR)
- LNZA 0.04
- IMMX 0.18
- MACD
- LNZA -0.00
- IMMX 0.00
- Stochastic Oscillator
- LNZA 37.63
- IMMX 92.59
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.